Skip to content

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Bannon’s War Room | Episode 2362 | Morning Edition Hour 2 | Recorded December 9, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Bannon’s War Room | Episode 2361 | Morning Edition Hour 1 | Recorded December 9, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Nightly News Rebroadcast | December 8, 2022 | Video: 26 Minutes 48 Seconds | NTD

Show Me

Bannon’s War Room | Episode 2359 | Evening Edition | Recorded December 8, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Bannon’s War Room | Episode 2359 | Morning Edition Hour 2 | Recorded December 8, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Bannon’s War Room | Episode 2358 | Morning Edition Hour 1 | Recorded December 8, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Bannon’s War Room | Episode 2357 | Evening Edition | Recorded December 7, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Nightly News Rebroadcast | December 7, 2022 | Video: 26 Minutes 48 Seconds | NTD

Show Me

NTD News Today (Dec. 7, 2022): Study: George Soros Tied to 253 Media Groups; Georgia Senator Raphael Warnock Wins Re-Election

Show Me

Latest Jaw-Dropping Release from Elon Musk’s Twitter Files Stuns | Rubin Report | Video: 51 Minutes

Show Me

Michael Avenatti Gets 14-Year Sentence for Stealing Millions From Clients | Epoch Times

Show Me

Mainstream Media or Dumbstream Media? | The Sordid Story Of Michael Avenatti Seen Through Trump Deranged News Programs

Show Me

Bannon’s War Room | Episode 2356 | Morning Edition Hour 2 | Recorded December 7, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2355 | Morning Edition Hour 1 | Recorded December 7, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Dr. Naomi Wolf Confronts Yale for Crimes Against Students | Daily Clout | Video: 19 Minutes 55 Seconds

Show Me

It Never Was. | “Covid Is No Longer Mainly A Pandemic Of The Unvaccinated. Here’s Why.” | Washington Post

Show Me

Free Speech Makes Free People | FIRE

Show Me

Rumble and Law Professor Sue New York Attorney General to Block Online Hate Speech Law, Calling It a First Amendment ‘Double Whammy’ | Law & Crime

Show Me

Nightly News Rebroadcast | December 6, 2022 | Video: 26 Minutes 53 Seconds | NTD

Show Me

Bannon’s War Room | Episode 2354 | Evening Edition | Recorded December 6, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Bannon’s War Room | Episode 2353 | Morning Edition Hour 2 | Recorded December 6, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Bannon’s War Room | Episode 2352 | Morning Edition Hour 1 | Recorded December 6, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Nightly News Rebroadcast | December 5, 2022 | Video: 22 Minutes 12 Seconds | NTD

Show Me

Bannon’s War Room | Episode 2351 | Evening Edition | Recorded December 5, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Mike Davis On Twitter Hunter Biden Reveal: The Left Fears Twitter Much More Than Tiktok Because Musk Threatens Exposing Their Countless Fabrications | Video: 4 Minutes 45 Seconds

Show Me

NTD News Today Full Broadcast (Dec. 5, 2022) | DNC Panel Votes to Reshape Primary Calendar; Special Counsel Asks Court to Halt Document Review |NTD

Show Me

Bannon’s War Room | Episode 2350 | Morning Edition Hour 2 | Recorded December 5, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Bannon’s War Room | Episode 2349 | Morning Edition Hour 1 | Recorded December 5, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Assisted Suicide: Canada Slides Down Slippery Slope; Montana Left in Legal Limbo | The Nation Speaks

Show Me

Elon Musk Bans Kanye West: What Principles Govern Twitter? | Glenn Greenwald l Video: 30 Minutes 21 Seconds

Show Me

Nightly News Rebroadcast | December 2, 2022 | Video: 26 Minutes 44 Seconds | NTD

Show Me

Bannon’s War Room | Episode 2348 | Saturday Edition Hour 2 | Recorded December 3, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Bannon’s War Room | Episode 2347 | Saturday Edition Hour 1 | Recorded December 3, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Bannon’s War Room | Episode 2346 | Evening Edition | Recorded December 2, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Oh, Oh. Sounds Like A Democrat Party Establishment Paradise | Step, On Up, Folks. Step On Up. Uyghurs For Sale! | “Uyghurs For Sale” | Australian Strategic Policy Institute

Show Me

Bannon’s War Room | Episode 2345 | Morning Edition Hour 2 | Recorded December 2, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2344 | Morning Edition Hour 1 | Recorded December 2, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Twitter Under Elon Musk Must Be Stopped! Otherwise, Americans May See What The Left Has Done To Our Society | The Hodge Brothers

Show Me

Bannon’s War Room | Episode 2343 | Evening Edition | Recorded December 1, 2022 | Video: 48 Minutes 57 Seconds

Show Me

Nightly News Rebroadcast | December 1, 2022 | Video: 26 Minutes 59 Seconds | NTD

Show Me